Abstract:In recent years, the incidence and mortality of advanced lung cancer in elderly patients have been increasing, but the number of elderly patients with lung cancer who receive active treatment is less than that of lung caner patients in other age stage. Molecular targeted therapies, such as the human epidermal growth factor tyrosine kinase inhibitors, angiogenesis inhibitors, anti-tumor monoclonal antibodies and multi-target drugs, have prolonged the overall survival and improved the life quality of elderly patients with advanced non-small cell lung cancer. Targeted therapy has become the most promising treatment and can significantly improve the prognosis of elderly patients.

Key words:Aged,Carcinoma, non-small-cell lung,Epidermal growth factor,Targeting therapy